Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company ...

It’s Alzheimer’s drug Simufilam did not show a significant reduction in ... Dave Bartosiak's technical analysis approach adds depth to our understanding Cassava Sciences’ stock chart. By paying ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

Cassava Sciences announced Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are ...